---
schema_version: "secwatch.filing_event.v1"
accession: "0001824293-22-000021"
form_type: "8-K"
ticker: "GRI"
cik: "0001824293"
company_name: "GRI Bio, Inc."
filed_at: "2022-03-30T23:59:59+00:00"
generated_at: "2026-06-26T13:55:00.059080+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Chairman Ofir Levi resigns from Vallon board; stays as consultant for 12 months at $22,500/quarter

## Summary
- Ofir Levi resigned as Board member and Chairman effective March 28, 2022, for personal reasons.
- Levi enters 12-month consulting agreement for $22,500 per quarter; unvested options vested immediately.
- Vested options remain exercisable during consulting term and 90 days thereafter.
- Resignation not due to any disagreement with management or operations.

## SEC filing metadata
- accession: 0001824293-22-000021
- form_type: 8-K
- ticker: GRI
- cik: 0001824293
- company_name: GRI Bio, Inc.
- filed_at: 2022-03-30T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824293/000182429322000021/0001824293-22-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824293/000182429322000021/ck00018242493-20220328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001824293-22-000021
- JSON: https://secwatch.observer/filing/0001824293-22-000021.json
- Plain text: https://secwatch.observer/filing/0001824293-22-000021.txt

## Key facts
- Executive change
  Ofir Levi resigned as Chairman of the Board at GRI Bio, Inc..
  - Action: resigned
  - Role: Chairman of the Board
  source text: On March 28, 2022, Ofir Levi resigned as a member of the Board of Directors (the “Board”) of Vallon Pharmaceuticals, Inc. (the “Company”) and as Chairman of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1824293/000182429322000021/0001824293-22-000021-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.